Since Quality of Life is increasingly more often used as a therapeutic endpoint in clinical trials, it is essential that the same level of scientific rigour is applied to these assessments. The draft guidelines issued by the Food and Drug Administration as well as with the Common Market are therefore welcomed.
No takes yet. Share an insight, caveat, or question.
Ingela Wiklund (1996) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: